Stage (next event)
Catalyst Info & Data Links
TITLE: POSIMIR®(bupivacaine extended-release solution) for Post Operative Pain - NDA Acceptance
ClinicalTrials.gov (NCT02574520): Trial of Extended Release Bupivacaine for Pain Relief After Surgery (PERSIST)
WHAT IS THE NEXT CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
TBD (Latest Quarterly Call says its under review)
2016: SABER®-Bupivacaine Reduces Postoperative Pain and Opioid Consumption Following Arthroscopic Subacromial Decompression 17th Annual European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress; 2016 Jun 1-3.
2016: Long-Term Safety of SABER®-Bupivacaine in Arthroscopic Subacromial Decompression 17th Annual European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress; 2016 Jun 1-3.
2016: A new method for treating postoperative pain associated with laparoscopic surgery. Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting; 2016 Mar 16-19.
Mechanism of Action
MECHANISM OF ACTION
POSIMIR is the Company's investigational post-operative pain relief depot product that utilizes DURECT's patented SABER® technology. POSIMIR is designed to be administered directly into the surgical site to deliver bupivacaine for up to three days after surgery.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post